NCT05476588

Brief Summary

The goal of this study is to validate the TAPS-ESP as a screen and assessment that can be used in primary care for the screening and treatment of substance use.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 1, 2022

Completed
14 days until next milestone

Study Start

First participant enrolled

July 15, 2022

Completed
12 days until next milestone

First Posted

Study publicly available on registry

July 27, 2022

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 14, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 14, 2024

Completed
Last Updated

January 26, 2026

Status Verified

October 1, 2025

Enrollment Period

1.7 years

First QC Date

July 1, 2022

Last Update Submit

January 23, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Tobacco, Alcohol, Prescription drug, and illicit Substance Use Tool-Electronic Spanish Platform (TAPS-ESP) primary criterion validation against the modified World Mental Health Composite International Diagnostic Interview (CIDI) in Spanish

    TAPS-ESP is a two-stage screening and assessment tool that first screens for 4 broad substance abuse categories (tobacco, alcohol, prescription drug misuse, and illicit substances), then branches to the assessment for specific risks related to an array of substances. TAPS-ESP scores will be validated against the modified World Mental Health Composite International Diagnostic Interview (CIDI) including alcohol, tobacco, and 9 substance categories. The CIDI items mapped to the diagnostic criteria for each substance will serve as the primary criterion standard for validation of the TAPS-ESP. For detecting CIDI-derived substance use disorder (SUD) diagnosis, we will examine TAPS-ESP cut-points for the 4-item screener and the assessment in detecting problem severity defined by CIDI for detecting different tiers of substance use: Problem use (1+ criteria), SUD (2+ criteria), and moderate-to-severe SUD (4-11 criteria). Detection of SUD will be the primary outcome for each substance category.

    1 year

Secondary Outcomes (5)

  • Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) for concurrent and convergent validity of the TAPS Tool

    1 year

  • Drug Abuse Screening Test (DAST-10) for concurrent and convergent validity of the TAPS Tool

    1 year

  • CAGE (Cut Down, Annoyed, Guilty, Eye-Opener) for concurrent and convergent validity of the TAPS

    1 year

  • Alcohol Use Disorders Identification Test (AUDIT) for concurrent and convergent validity of the TAPS

    1 year

  • Fagerstrom Test for Nicotine Dependence (FTND) for concurrent and convergent validity of the TAPS

    1 year

Study Arms (2)

Self-Administration followed by Interviewer-Administered

ACTIVE COMPARATOR

Screening and validation of assessment tool translated into Spanish

Other: Screening

Interviewer-Administered followed by Self-Administration

ACTIVE COMPARATOR

Screening and validation of assessment tool translated into Spanish

Other: Screening

Interventions

Screening and validation of assessment tool translated into Spanish

Interviewer-Administered followed by Self-AdministrationSelf-Administration followed by Interviewer-Administered

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18 or older
  • Current patient of the clinic
  • Spanish-language preferred
  • Ability to read Spanish

You may not qualify if:

  • Unable to provide informed consent
  • Inability to comprehend or read Spanish
  • Inability to self-administer the iPad tool due to physical limitations

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Baylor Scott and White Community Care

Dallas, Texas, 75246, United States

Location

Related Publications (1)

  • Gryczynski J, Sanchez K, Carswell SB, Schwartz RP. The Spanish language version of the TAPS tool: protocol for a validation and implementation study in primary care. Addict Sci Clin Pract. 2023 Nov 16;18(1):69. doi: 10.1186/s13722-023-00423-9.

MeSH Terms

Conditions

Tobacco UseAlcoholismSubstance-Related Disorders

Interventions

Mass Screening

Condition Hierarchy (Ancestors)

BehaviorAlcohol-Related DisordersChemically-Induced DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Diagnostic Techniques and ProceduresDiagnosisHealth SurveysSurveys and QuestionnairesData CollectionEpidemiologic MethodsInvestigative TechniquesDiagnostic ServicesPreventive Health ServicesHealth ServicesHealth Care Facilities Workforce and ServicesHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public HealthPublic Health Practice

Study Officials

  • Katherine Sanchez, PhD

    Baylor Scott and White Research Institute

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SCREENING
Intervention Model
PARALLEL
Model Details: randomized, two-group design.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 1, 2022

First Posted

July 27, 2022

Study Start

July 15, 2022

Primary Completion

March 14, 2024

Study Completion

March 14, 2024

Last Updated

January 26, 2026

Record last verified: 2025-10

Data Sharing

IPD Sharing
Will share
Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
Two years
Access Criteria
Contact Principal Investigators

Locations